EUVIMEDEUVIMED entdecken
Fallbericht

A case of bullous pemphigoid developing under treatment with benralizumab for bronchial asthma

Arisa Tanaka iD, Yu Fujimura, Satoshi Fuke, Kentaro Izumi, Hideyuki Ujiie iD

The Journal of Dermatology · 2023

DOI: 10.1111/1346-8138.16811 ↗

Kurz gefasst

Fallbericht in der Zeitschrift The Journal of Dermatology, 2023. Verfasst von Arisa Tanaka und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, KKR Sapporo Medical Center, Sapporo, Japan. Hauptthemen laut MEDLINE: Pemphigoid, Bullous, Asthma, Pulmonary Eosinophilia. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bullous pemphigoid (BP) is an autoimmune disease characterized by itchy erythema and tense blisters on the whole body. Recent reports have unveiled the pathogenic roles of eosinophils in BP (e.g., dermal‐epidermal separation, generation of pruritus). Thus, eosinophils are considered a therapeutic target. Benralizumab is an anti‐IL‐5 receptor alpha (IL‐5Rα) monoclonal antibody (mAb) that is widely used to treat severe eosinophilic asthma. By affecting IL‐5Rα, benralizumab depletes eosinophils and basophils due to apoptosis through antibody‐dependent cell‐mediated cytotoxicity. The efficacies of benralizumab and other biologics, including bertilimumab (anti‐eotaxin‐1 mAb) and mepolizumab (anti‐IL‐5 mAb), were evaluated in several clinical trials. Also, reslizumab, an anti‐IL‐5 mAb, was reported as a successful treatment option in a case of BP. We present a case of severe asthma treated with benralizumab at 8‐week intervals for 3 years before BP developed. Histologically, subepidermal blisters without eosinophilic infiltration were observed. Methylprednisolone pulse therapy followed by 40 mg/day (1 mg/kg/day) of oral prednisolone (PSL) was initiated, but the skin lesions worsened. Additional intravenous immunoglobulin and oral azathioprine enabled the oral PSL to be tapered. The benralizumab was discontinued after the onset of BP because the asthma did not worsen. To the best of our knowledge, there have been no reports of BP developing during anti‐eosinophil therapy. BP may occur paradoxically via various pathways during treatment with drugs that are typically effective against BP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pemphigoid, BullousAsthmaPulmonary EosinophiliaHumansBlisterAntibodies, MonoclonalPrednisoloneAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

anti-IL-5 receptor alpha monoclonal antibody (anti-IL-5Rα mAb)bullous pemphigoideosinophileotaxininterleukin (IL)-5

Substanzen

Antibodies, MonoclonalPrednisolonebenralizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Dermatology, KKR Sapporo Medical Center, Sapporo, Japan.
  • Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
  • Department of Respiratory Medicine, KKR Sapporo Medical Center, Sapporo, Japan.

ORCID-Profile: Arisa Tanaka, Hideyuki Ujiie

Zitieren

APA

Tanaka, A., Fujimura, Y., Fuke, S., Izumi, K., & Ujiie, H. (2023). A case of bullous pemphigoid developing under treatment with benralizumab for bronchial asthma. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.16811

Vancouver

Tanaka A, Fujimura Y, Fuke S, Izumi K, Ujiie H. A case of bullous pemphigoid developing under treatment with benralizumab for bronchial asthma. The Journal of Dermatology. 2023. doi:10.1111/1346-8138.16811

BibTeX
@article{Tanaka2023,
  author = {Tanaka, Arisa and Fujimura, Yu and Fuke, Satoshi and Izumi, Kentaro and Ujiie, Hideyuki},
  title = {A case of bullous pemphigoid developing under treatment with benralizumab for bronchial asthma},
  journal = {The Journal of Dermatology},
  year = {2023},
  doi = {10.1111/1346-8138.16811}
}
Kostenlos starten →